SEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.
$SABS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
SAB Biotherapeutics, Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
78397T202 (CUSIP Number) |
09/30/2025 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 78397T202 |
| 1 | Names of Reporting Persons
Woodline Partners LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
7,125,881.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
9.9 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IA, PN |
Comment for Type of Reporting Person: Consists of (i) 2,850,881 shares of Common Stock (as defined in Item 2(a)), (ii) 2,850,000 shares of Common Stock issuable upon conversion of 28,500 shares of Series B preferred stock (the "Series B Preferred Stock") underlying 28,500 enrollment warrants (the "Enrollment Warrants") and (iii) 1,425,000 shares of Common Stock issuable upon conversion of 14,250 shares of Series B Preferred Stock underlying 14,250 data release warrants (the "Data Release Warrants"). The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrants contain certain provisions (the "Blockers") preventing these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder (or its affiliates or certain related parties) beneficially owning greater than 9.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion or exercise, as applicable. However, the amounts reported in rows 5, 7 and 9 herein include the number of shares of Common Stock that would be issuable upon full exercise of the Data Release Warrants and Enrollment Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the Blockers.
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
SAB Biotherapeutics, Inc. | |
| (b) | Address of issuer's principal executive offices:
777 W 41st St, Suite 401, Miami Beach, Florida 33140 | |
| Item 2. | ||
| (a) | Name of person filing:
This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of SAB Biotherapeutics, Inc. (the "Company"), and shares of Common Stock issuable upon the conversion of Series B Preferred Stock issuable upon the exercise of the Data Release Warrants and Enrollment Warrants, directly held by the Woodline Fund.
The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein. | |
| (b) | Address or principal business office or, if none, residence:
The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. | |
| (c) | Citizenship:
Woodline Partners is a Delaware limited partnership. | |
| (d) | Title of class of securities:
Common Stock, par value $0.0001 per share | |
| (e) | CUSIP No.:
78397T202 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 45,108,294 shares of Common Stock outstanding as of September 30, 2025, as disclosed by the Company to the Reporting Person, and assumes the conversion of the Series B Preferred Stock issuable upon the exercise of the Enrollment Warrants and the Data Release Warrants held by the Woodline Fund subject to the Blockers.
The Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrants contain Blockers that prevent these securities from being converted or exercised into shares of Common Stock, if such conversion or exercise would result in the holder (or its affiliates or certain related parties) beneficially owning greater than 9.99% of the shares of Common Stock outstanding immediately after giving effect to such conversion or exercise, as applicable. However, the amounts set forth in rows 5, 7 and 9 of the cover page for the Reporting Person include the number of shares of Common Stock that would be issuable upon full exercise of the Data Release Warrants and Enrollment Warrants into Series B Preferred Stock and the full conversion of Series B Preferred Stock to shares of Common Stock, without giving effect to the Blockers. Consequently, at this time, the Reporting Person is not able to exercise all of such Series B Preferred Stock, the Enrollment Warrants and the Data Release Warrants due to the Blockers. | |
| (b) | Percent of class:
9.9% | |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. | ||
| (ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. | ||
| (iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. | ||
| (iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Woodline Fund has right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. | ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|